Troutman Pepper represented Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company based in Victoria, British Columbia, in its non-brokered private placement of 8,905,638 Series 1 preferred shares of the company, at a price of C$5.00 per preferred share for aggregate gross proceeds of C$44,528,190. Read a company press release about the private placement.

The company intends to use the net proceeds from the private placement towards the funding of clinical trials for EP104GI for treatment of eosinophilic esophagitis, initiating research programs for new candidates, and general corporate and working capital purposes of the company and its affiliates.

The Troutman Pepper team advising Eupraxia Pharmaceuticals was led by Thomas Rose, and included Shona Smith, Nicole Edmonds, Jason Langford, Joseph Cataldo, Judith O’Grady, Noreen Onimus, and Thomas Phelan.